ANTIBODIES AGAINST TL1A AND USES THEREOF

The present disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3)....

Full description

Saved in:
Bibliographic Details
Main Authors TAMVAKIS, DEBRA, KOPSIDAS, GEORGE, POULTON, LYNN DOROTHY, POW, ANDREW JAMES, CLARKE, ADAM, JENNINGS, PHILIP ANTHONY, POLLARD, MATTHEW, DOYLE, ANTHONY GERARD
Format Patent
LanguageEnglish
French
Published 14.03.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The present disclosure also provides uses of the TL1a-binding proteins. La présente invention concerne des protéines de liaison au ligand 1a de type TNF (TL1a), comprenant un domaine de liaison à un antigène d'un anticorps qui se lie spécifiquement à TL1a et inhibe une interaction de TL1a et du Récepteur 3 de Mort (DR3) et qui n'inhibe pas l'interaction de TL1a et du Récepteur 3 Leurre (DcR3). La présente invention concerne également des utilisations des protéines de liaison à TL1a.
Bibliography:Application Number: CA20122850549